Clay Siegall, Morphimmune CEO (Photo by Dimitrios Kambouris/Getty Images for Gabrielle's Angel Foundation)
May 18, 2023 10:28 AM EDTUpdated 11:18 AM
Financing
Startups

Short­ly af­ter Clay Sie­gall’s ar­rival, Philip Low’s Mor­phim­mune nabs funds for twist on can­cer ther­a­pies

Kyle LaHucik

Senior Reporter

Two months af­ter an­nounc­ing Clay Sie­gall’s ar­rival in the C-suite, Mor­phim­mune has nabbed more funds to take its tar­get­ed can­cer ther­a­py bet to­ward the clin­ic …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times